Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.
On 30 September 2011, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £13.40 per Ordinary share and $41.61 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2011 to 30 September 2011:
Non Executive Director
|
Ordinary Shares
|
American Depository Shares (ADSs)
|
|
|
|
Sir Christopher Gent
|
2,518.657
|
|
|
|
|
Prof. Sir Roy Anderson
|
489.739
|
|
|
|
498.315
|
Dr Stephanie Burns
|
|
|
|
|
|
Ms Stacey Cartwright
|
349.813
|
|
Mr Lawrence Culp |
|
996.629 |
|
|
|
Sir Crispin Davis
|
1,772.388
|
|
|
|
|
Ms Judy Lewent
|
|
249.157
|
Sir Deryck Maughan |
|
711.878 |
|
|
|
Mr James Murdoch
|
1,399.254
|
|
|
|
|
Dr Daniel Podolsky
|
|
961.036
|
|
|
|
Mr Tom de Swaan
|
722.948
|
|
Sir Robert Wilson
|
489.739
|
|
|
The Company and the Non-Executive Directors were informed of these allocations on 3 October 2011.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
3 October 2011